Journal of Immune Based Therapies and Vaccines

Table 1 Patient Characteristics (Intent-To-Treat Population)

From: IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study

Parameter	Engerix^®-B	HBsAg alone	HBsAg + 3 μg IMP321	HBsAg + 10 μg IMP321	HBsAg + 30 μg IMP321	HBsAg + 100 μg IMP321
Number enrolled	8	8	9	9	8	8
Number completed	8	8	8	8	8	8
Age (years)^a Mean ± SD	32.1 ± 11.2	41.0 ± 11.4	31.4 ± 8.0	29.0 ± 9.2*	37.3 ± 9.7	35.9 ± 7.4
Gender^b
Male	7	7	9	9	8	8
Female	1	1	0	0	0	0
Race^b
Caucasian	7	6	6	5	6	7
Black	1	1	1	2	2	1
Asian	0	0	1	1	0	0
Other	0	1	1	1	0	0

^a Student's t-test. * p < 0.05 compared to HBsAg alone control group.
^b Chi-square. P >0.05 compared to HBsAg alone control group.

Back to article page